TYROSINE KINASES IN CANCER RECURRENCE
With
Dr Yu Yu
Program Lead, Curtin Medical Research Institute &
Senior Research Fellow, Curtin Medical School,
Curtin University, Perth, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | July 2025
Dr Yu Yu completed her PhD at Faculty of Medicine, University of Sydney in experimental therapeutics for cancer. She then pursued postdoctoral training at the Richard W. TeLinde Gynecologic Pathology Laboratory, Johns Hopkins University School of Medicine, USA with a focus on understanding the treatment for recurrent ovarian tumour.
Dr Yu Yu leads the Oncology and Gynaecology Research Program at Curtin Medical Research Institute . Dr Yu is also a senior research fellow at Curtin Medical School.
Dr Yu Yu has a strong expertise in developing molecular and cellular therapeutics for cancer. She is a former NHMRC Peter Doherty Fellow and Raine/Robson Fellow. Her studies focused on recurrent cancers, with interests in biomarker and therapeutics development.
Ovarian cancer is one of the deadliest gynaecologic cancers. There are ~300,000 new cases of ovarian cancer worldwide each year. Less than half of women diagnosed survive 5-years after diagnosis. Platinum-based chemotherapy is used to treat ovarian cancers and a variety of other solid cancers. The National Cancer Institute reports 20% of cancer patients worldwide (3.6 million people) receive a platinum-based drug as part of treatment. However, ~20-50% do not respond because of intrinsic resistance. Currently, there is no way to predict response prior to starting platinum chemotherapy.
Dr Yu Yu’s laboratory is working on better ways to treat cancers, particularly ovarian cancers which are resistant to conventional chemotherapy. The aims are for better informed treatment choice and reducing unnecessary exposure to ineffective chemotherapy and its potential adverse effects.
Collaboration partners include St John of God Hospital and King Edward Memorial Hospital, both in Western Australia. Funding for Dr Yu Yu’s research comes from WA Department of Health’s Future Health and Innovation Research Fund, Raine Medical Research Foundation and Endometriosis Foundation of America.
Source: Supplied and adapted
https://orcid.org/0000-0002-0209-0586
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Next Generation Condom Contraception, Dr Simon Cook
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
-
Using Gut Microbes to Reduce Blood Pressure
Professor Francine Marques is an National Health and Medical Research Council Emerging Leader, Viertel Charitable Foundation, and National Heart Foundation Fellow.
She leads the Hypertension Research Laboratory at Monash University and has published more than 120 peer-reviewed papers in journals such as Nature Reviews Cardiology, Nature Medicine, Nature Cardiovascular Research, and Circulation.
